- Home
- NMS vs BMEA Comparison
NMS vs BMEA Comparison
Compare NMS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- BMEA
- Stock Information
- Founded
- NMS 1993
- BMEA 2017
- Country
- NMS United States
- BMEA United States
- Employees
- NMS N/A
- BMEA N/A
- Industry
- NMS Finance Companies
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- BMEA Health Care
- Exchange
- NMS Nasdaq
- BMEA Nasdaq
- Market Cap
- NMS 67.0M
- BMEA 65.8M
- IPO Year
- NMS N/A
- BMEA 2021
- Fundamental
- Price
- NMS $11.36
- BMEA $1.58
- Analyst Decision
- NMS
- BMEA Strong Buy
- Analyst Count
- NMS 0
- BMEA 10
- Target Price
- NMS N/A
- BMEA $21.00
- AVG Volume (30 Days)
- NMS 12.0K
- BMEA 834.0K
- Earning Date
- NMS 01-01-0001
- BMEA 08-12-2025
- Dividend Yield
- NMS 4.11%
- BMEA N/A
- EPS Growth
- NMS N/A
- BMEA N/A
- EPS
- NMS N/A
- BMEA N/A
- Revenue
- NMS N/A
- BMEA N/A
- Revenue This Year
- NMS N/A
- BMEA N/A
- Revenue Next Year
- NMS N/A
- BMEA N/A
- P/E Ratio
- NMS N/A
- BMEA N/A
- Revenue Growth
- NMS N/A
- BMEA N/A
- 52 Week Low
- NMS $9.21
- BMEA $1.29
- 52 Week High
- NMS $12.18
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- NMS 55.60
- BMEA 38.61
- Support Level
- NMS $11.30
- BMEA $1.53
- Resistance Level
- NMS $11.44
- BMEA $1.75
- Average True Range (ATR)
- NMS 0.09
- BMEA 0.10
- MACD
- NMS 0.03
- BMEA -0.02
- Stochastic Oscillator
- NMS 78.38
- BMEA 11.49
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.